{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:05:39Z","timestamp":1790024739125,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.remnie.2026.500336","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:37:59Z","timestamp":1788190679000},"page":"500336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical consensus document on the use of [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer"],"prefix":"10.1016","author":[{"given":"N.","family":"\u00c1lvarez Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"G\u00f3mez-Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nogareda Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Prado Wohlwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodr\u00edguez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodr\u00edguez Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Vercher Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mitjavila Casanovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2026.500336_bib0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0010","series-title":"FDA approves lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer","year":"2022"},{"key":"10.1016\/j.remnie.2026.500336_bib0015","series-title":"Pluvicto (lutetium [177Lu] vipivotide tetraxetan): EPAR - product information","year":"2022"},{"key":"10.1016\/j.remnie.2026.500336_bib0020","series-title":"Informe de Posicionamiento Terap\u00e9utico de lutecio (177Lu) vipivotida tetraxet\u00e1n (Pluvicto\u00ae) en c\u00e1ncer de pr\u00f3stata metast\u00e1sico resistente a la castraci\u00f3n","year":"2024"},{"key":"10.1016\/j.remnie.2026.500336_bib0025","series-title":"Pluvicto (lutecio [177Lu] vipivotida tetraxet\u00e1n): ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto","year":"2022"},{"key":"10.1016\/j.remnie.2026.500336_bib0030","series-title":"FDA expands Pluvicto\u2019s indication for metastatic castration-resistant prostate cancer","year":"2025"},{"key":"10.1016\/j.remnie.2026.500336_bib0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"A randomised controlled phase 3 trial of lutetium-177-PSMA-617 in taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.remnie.2026.500336_bib0040","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0045","series-title":"Informe p\u00fablico sobre la decisi\u00f3n de inclusi\u00f3n en la prestaci\u00f3n farmac\u00e9utica de lutecio (177Lu) vipivotida tetraxet\u00e1n (Pluvicto\u00ae) en el tratamiento del c\u00e1ncer de pr\u00f3stata metast\u00e1sico","year":"2025"},{"key":"10.1016\/j.remnie.2026.500336_bib0050","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0055","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology."},{"key":"10.1016\/j.remnie.2026.500336_bib0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"10.1016\/j.remnie.2026.500336_bib0065","first-page":"1932","article-title":"Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [177Lu]Lu-PSMA-617","volume":"65","author":"Muniz","year":"2024","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12149-025-02127-3","article-title":"Efficacy and safety of lutetium-177 (177Lu)-PSMA-617 in metastatic castration-resistant prostate cancer patients with superscan pattern: a retrospective cohort study","volume":"40","author":"Shamshirgaran","year":"2026","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0075","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500336_bib0080","series-title":"Directiva 2013\/59\/Euratom del Consejo, de 5 de diciembre de 2013, por la que se establecen normas b\u00e1sicas de seguridad para la protecci\u00f3n contra los peligros derivados de la exposici\u00f3n a radiaciones ionizantes","year":"2014"},{"key":"10.1016\/j.remnie.2026.500336_bib0085","series-title":"Real Decreto 1029\/2022, de 20 de diciembre, por el que se aprueba el Reglamento sobre protecci\u00f3n de la salud contra los riesgos derivados de la exposici\u00f3n a las radiaciones ionizantes","first-page":"305","year":"2022"},{"key":"10.1016\/j.remnie.2026.500336_bib0090","series-title":"Real Decreto 601\/2019, de 18 de octubre, sobre justificaci\u00f3n y optimizaci\u00f3n del uso de las radiaciones ionizantes para la protecci\u00f3n radiol\u00f3gica de las personas con ocasi\u00f3n de exposiciones m\u00e9dicas","first-page":"262","year":"2019"},{"key":"10.1016\/j.remnie.2026.500336_bib0095","series-title":"Real Decreto 673\/2023, de 18 de julio, por el que se establecen los criterios de calidad y seguridad de las unidades asistenciales de medicina nuclear","first-page":"171","year":"2023"},{"key":"10.1016\/j.remnie.2026.500336_bib0100","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500336_bib0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.remnie.2026.500336_bib0110","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0115","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","article-title":"Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy","volume":"65","author":"Yadav","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500336_bib0120","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/pros.23974","article-title":"Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"80","author":"Derlin","year":"2020","journal-title":"Prostate."},{"key":"10.1016\/j.remnie.2026.500336_bib0125","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/pros.24219","article-title":"Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer","volume":"81","author":"Suman","year":"2021","journal-title":"Prostate."},{"key":"10.1016\/j.remnie.2026.500336_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","author":"Rosar","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.remnie.2026.500336_bib0135","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","article-title":"Impact of post-therapeutic whole-body scintigraphy in PSMA-targeted therapy","volume":"47","author":"Maffey-Steffan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500336_bib0140","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de Pluvicto 1.000 MBq\/ml soluci\u00f3n inyectable y para perfusi\u00f3n. Madrid: Centro de Informaci\u00f3n online de Medicamentos (CIMA). Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1221703001\/FT_1221703001.html."},{"key":"10.1016\/j.remnie.2026.500336_bib0145","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2967\/jnmt.123.266482","article-title":"Critical challenges in Pluvicto therapy: incontinent and anticoagulated patients","volume":"51","author":"Crowley","year":"2023","journal-title":"J Nucl Med Technol."},{"key":"10.1016\/j.remnie.2026.500336_bib0155","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","article-title":"SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500336_bib0160","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2967\/jnumed.124.268363","article-title":"Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy","volume":"65","author":"Calais","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500336_bib0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.remnie.2026.500336_bib0170","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data","volume":"65","author":"Murthy","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500336_bib0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.124.268640","article-title":"Therapy-related myeloid neoplasms after [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series","volume":"66","author":"Eifer","year":"2025","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0180","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0","year":"2017"},{"key":"10.1016\/j.remnie.2026.500336_bib0185","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.remnie.2026.500336_bib0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2023","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101445","article-title":"Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management","volume":"21","author":"Mahajan","year":"2022","journal-title":"Transl Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0200","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1007\/s00259-023-06328-8","article-title":"Urinary excretion kinetics of [177Lu]Lu-PSMA-617","volume":"50","author":"De Bakker","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500336_bib0205","series-title":"NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Version 2026","year":"2026"},{"key":"10.1016\/j.remnie.2026.500336_bib0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0215","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","article-title":"[177Lu]Lu-PSMA-617 in oligometastatic hormone-sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study","volume":"27","author":"Priv\u00e9","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0225","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [177Lu]Lu-PSMA: a German multicenter study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0230","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2967\/jnumed.125.271231","article-title":"Phase 2 prospective trial of retreatment with [177Lu]Lu-PSMA-617 molecular radiotherapy for metastatic castration-resistant prostate cancer (RE-LuPSMA)","volume":"67","author":"Nikitas","year":"2026","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0235","first-page":"1300","article-title":"Rechallenge and extended [177Lu]Lu-PSMA therapy in metastatic prostate cancer","volume":"66","author":"Mirshahvalad","year":"2025","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2967\/jnumed.125.270170","article-title":"Lesion absorbed dose-response relationship in mCRPC undergoing [177Lu]Lu-PSMA-617 therapy","volume":"66","author":"Grkovski","year":"2025","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0245","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00259-026-07823-4","article-title":"Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617","volume":"53","author":"Dieudonn\u00e9","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500336_bib0250","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2025.05.014","article-title":"Machine learning-based dose prediction in [177Lu]Lu-PSMA-617 therapy by integrating biomarkers and radiomic features from [68Ga]Ga-PSMA-11 positron emission tomography\/computed tomography","volume":"123","author":"Yazdani","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"16 Suppl","key":"10.1016\/j.remnie.2026.500336_bib0255","article-title":"PSMA expression and response to 177Lu-PSMA-617 in men with and without DNA damage repair mutations","volume":"41","author":"Raychaudhuri","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0260","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","article-title":"Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers","volume":"64","author":"Sartor","year":"2023","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2967\/jnumed.120.256263","article-title":"Mechanisms of resistance to PSMA-targeted radioligand therapy in a mouse model","volume":"62","author":"Stuparu","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0270","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0275","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"Men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I\/II trial","volume":"63","author":"Pathmanandavel","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500336_bib0280","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","article-title":"Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial","volume":"26","author":"Kostos","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500336_bib0285","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2967\/jnumed.125.270317","article-title":"Combining PSMA-targeted radiopharmaceutical therapy with immunotherapy","volume":"66","author":"Altunay","year":"2025","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500336_bib0290","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.119.234559","article-title":"Patients resistant to PSMA-targeting \u03b1\u2013radiation therapy often harbor DDR-associated mutations","volume":"61","author":"Kratochwil","year":"2020","journal-title":"J Nucl Med."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:29:13Z","timestamp":1790022553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808926000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"alternative-id":["S2253808926000753"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500336","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical consensus document on the use of [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2026.500336","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500336"}}